tetano
Editor, Senior Moderator
PLoS One
. 2021 Feb 17;16(2):e0237480.
doi: 10.1371/journal.pone.0237480. eCollection 2021.
Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro
Martina Morokutti-Kurz[SUP] 1 [/SUP], Maria Fr?ba[SUP] 2 [/SUP], Philipp Graf[SUP] 1 [/SUP], Maximilian Gro?e[SUP] 2 [/SUP], Andreas Grassauer[SUP] 1 [/SUP], Janina Auth[SUP] 2 [/SUP], Ulrich Schubert[SUP] 2 [/SUP], Eva Prieschl-Grassauer[SUP] 1 [/SUP]
Affiliations
Abstract
In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.
. 2021 Feb 17;16(2):e0237480.
doi: 10.1371/journal.pone.0237480. eCollection 2021.
Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro
Martina Morokutti-Kurz[SUP] 1 [/SUP], Maria Fr?ba[SUP] 2 [/SUP], Philipp Graf[SUP] 1 [/SUP], Maximilian Gro?e[SUP] 2 [/SUP], Andreas Grassauer[SUP] 1 [/SUP], Janina Auth[SUP] 2 [/SUP], Ulrich Schubert[SUP] 2 [/SUP], Eva Prieschl-Grassauer[SUP] 1 [/SUP]
Affiliations
- PMID: 33596218
- DOI: 10.1371/journal.pone.0237480
Abstract
In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.